FDA Financial Disclosure & Investigator COI — Biotech Scenario

Your Lead Clinical Investigator Holds Equity in Your Company. The Trial Data Is Strong. Do You Have to Disclose It to the FDA?

A real biotech and pharma compliance scenario — with three decision options and the right answer.

The Situation

You are the head of clinical operations at a biotech company preparing to submit a New Drug Application (NDA) to the FDA for your lead compound. The Phase 3 trial was led by a highly respected principal investigator at a major academic medical center. The results are strong — and this investigator was instrumental in recruiting sites, designing the endpoints, and building the trial’s credibility. During NDA preparation, you learn that this investigator holds equity in your company worth approximately $75,000, acquired through an early advisory relationship several years ago. The equity was disclosed to their institution at the time but was never formally reported to your regulatory affairs team. Your regulatory affairs director raises the disclosure requirement under the FDA’s financial disclosure rules. A senior colleague pushes back: disclosing the equity interest now will invite FDA scrutiny of the trial results — possibly delaying approval by months. “The investment is small,” the colleague argues. “It won’t affect the review.”

Choice ADisclose the financial interest in the NDA submission. Report the investigator’s equity stake in Form FDA 3455 as required, and provide a certification that steps were taken to minimize the potential for bias.

Choice BDo not disclose, on the grounds that the interest is immaterial and the data is reliable. Treat the equity position as too small to affect the investigator’s objectivity and proceed without disclosure, focusing on the strength of the data itself.

Choice CRemove the investigator from the NDA submission entirely. Exclude the sites managed by this investigator from the dataset to avoid the disclosure issue altogether.

The Right Call

Choice A — Disclose the financial interest.

FDA regulations under 21 CFR Part 54 require sponsors to certify the absence of disqualifying financial interests or to disclose covered financial interests for clinical investigators whose data is included in a marketing application. An equity interest worth $75,000 in the sponsor company is a covered financial interest that must be disclosed — the regulation does not include an exception for interests that the sponsor believes are immaterial. Choice B is a regulatory violation: the decision about whether the financial interest is material belongs to the FDA, not the sponsor. Choice C avoids the disclosure issue but creates a different problem — if this investigator led significant trial sites, excluding their data may materially affect the statistical analysis and raises questions about why those sites were excluded.

The colleague’s argument about scrutiny is not wrong — disclosure does invite scrutiny.

When a sponsor discloses an investigator’s financial interest, the FDA reviews the submission with that interest in mind. In some cases, they request additional analysis to assess whether the interest could have introduced bias. This process takes time. For a sponsor in a competitive market or facing patent cliffs, a multi-month delay has real financial consequences. But the alternative — submitting an NDA with a known undisclosed financial interest — is far more dangerous. If the FDA identifies the omission, the sponsor faces regulatory fraud findings, a potential clinical hold on other programs, and reputational damage from appearing to have deliberately withheld information.

“The data is clean” is not the sponsor’s call to make.

The purpose of financial disclosure is not to allow sponsors to adjudicate whether bias occurred. It is to give the FDA the information it needs to make that assessment independently. A sponsor that decides unilaterally that its own trial data is unaffected by an investigator’s financial interest has compromised the independence of that review. The FDA’s ability to make credible regulatory decisions depends on sponsors providing complete information — including information that might invite questions.

Early advisory relationships are a common source of undisclosed conflicts of interest.

Many clinical investigators in biotech have historical advisory or consulting relationships with the companies whose trials they conduct. Equity granted years earlier — before a trial was designed — often falls outside the informal tracking systems companies have in place. The equity was legitimate at the time, the relationship has been productive, and by the time the NDA is being prepared, the interest has been forgotten or treated as immaterial. This pattern is exactly what the FDA’s financial disclosure rules are designed to surface.

Implement financial disclosure collection early — identify and document investigator financial interests at site initiation, not during NDA preparation.

Review 21 CFR Part 54 thresholds — proprietary interests, significant equity interests above $50,000, and payments above threshold must be disclosed. Train regulatory and clinical teams on what triggers reporting.

Disclose and provide context — when disclosing a financial interest, include a certification of steps taken to minimize bias. This demonstrates good faith and gives the FDA tools to assess the data.

Build a process for historical equity review — many companies lack a systematic way to capture equity interests from early advisory relationships. This gap is common and addressable with the right process at site activation.

What are the FDA’s financial disclosure requirements for clinical investigators?

Under 21 CFR Part 54, sponsors submitting marketing applications must provide financial information for each clinical investigator who conducted covered clinical studies. Covered financial interests include proprietary interests in the product, significant equity interests in the sponsor above $50,000 in value, and certain payments and compensation arrangements. Sponsors must either certify the absence of covered interests or disclose them, and must describe steps taken to minimize the potential for bias.

What is a “significant equity interest” under 21 CFR Part 54?

The FDA defines a significant equity interest as any financial interest in the sponsor of a covered clinical study that exceeds $50,000 in value, or any equity interest if the sponsor is not publicly traded. The $75,000 equity position in this scenario exceeds that threshold and is a covered financial interest requiring disclosure regardless of the sponsor’s view of its materiality.

What happens if the FDA identifies an undisclosed financial interest after an NDA submission?

The FDA may issue a deficiency letter requiring the missing financial information. In more serious cases, particularly where the omission appears deliberate, the FDA may issue a complete response letter declining to approve the application, refer the matter for regulatory fraud investigation, or place other programs under additional scrutiny. Post-approval, discovered omissions can affect the status of the marketing authorization.

Can a sponsor exclude an investigator’s data from an NDA to avoid financial disclosure?

No. Sponsors cannot selectively exclude investigator data to avoid triggering disclosure requirements. Excluding data from significant trial sites affects the statistical analysis and may compromise the integrity of the submission. The FDA expects sponsors to include all available data and address financial interests through proper disclosure mechanisms, not through exclusion of inconvenient datasets.

How should biotech companies manage investigator financial interests across a clinical program?

Best practice is to establish a financial disclosure tracking process at the start of each clinical program — collecting certifications or disclosure forms from investigators at site activation and updating them annually. This information should be managed by regulatory affairs in coordination with clinical operations, reviewed before key regulatory submissions, and retained in the trial master file. Companies with advisory boards or early-stage investigator relationships should track equity grants systematically from the time they are issued.

How to Use This Scenario in Training

Financial disclosure policy establishes the requirement. This scenario makes clear why it exists.

This scenario is most valuable for regulatory affairs, clinical operations, and legal and compliance teams at companies preparing IND submissions, conducting clinical trials, or approaching NDA or BLA submissions. The recognition skill is understanding that the FDA financial disclosure obligation belongs to the sponsor — not the investigator — and that the sponsor’s assessment of bias is not a substitute for proper disclosure.

More Compliance Scenarios

Compliance Training Built for Biotech and Pharma

Xcelus develops scenario-based compliance training for pharmaceutical and biotech organizations — including FDA financial disclosure, investigator conflict of interest, research integrity, and regulatory affairs compliance scenarios built for your clinical and regulatory teams.

View Compliance Programs →
Contact Xcelus